Brigatinib-based targeted drug conjugates afford selective and potent anti-tumor efficacy in the treatment of pancreatic ductal adenocarcinoma
Bioorganic Chemistry · 2026-09 · 180 · 110247
DOI: 10.1016/j.bioorg.2026.110247 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-09. Verfasst von Heng Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Pyrimidines. Die Arbeit nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal human malignancies, as existing therapies lack sufficient tumor selectivity and offer dose-limiting systemic toxicity. Herein report is the design, synthesis, and biological evaluation of five novel EGFR-targeted drug conjugates (TDCs) upon our TDC strategy, which employs Brigatinib as the targeting moiety linked to various cytotoxic payloads. Molecular docking-guided conjugation maintained EGFR binding affinity across all TDCs (IC50 = 0.14-0.24 nM), and the representative compound BG2 exhibited potent antiproliferative activity against PANC-1 cells (IC50 = 0.68 μM) with a high selectivity index relative to normal cells. Further investigations revealed a diverse antitumor profile, mainly including inhibition of the EGFR/AKT pathway and induction of DNA double-strand breaks. In a PANC-1 xenograft model, BG2 achieved 67.79% tumor growth inhibition while preserving organ histology and maintaining stable body weight. These findings highlight the potential of the Brigatinib-based TDC platform as a precision therapeutic strategy for PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China.
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China. Electronic address: xugang@seu.edu.cn.
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China. Electronic address: sgou@seu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, H., Yang, W., Ge, X., Xu, G., & Gou, S. (2026). Brigatinib-based targeted drug conjugates afford selective and potent anti-tumor efficacy in the treatment of pancreatic ductal adenocarcinoma. Bioorganic Chemistry, 180, 110247. https://doi.org/10.1016/j.bioorg.2026.110247
Vancouver
Zhang H, Yang W, Ge X, Xu G, Gou S. Brigatinib-based targeted drug conjugates afford selective and potent anti-tumor efficacy in the treatment of pancreatic ductal adenocarcinoma. Bioorganic Chemistry. 2026;180:110247. doi:10.1016/j.bioorg.2026.110247
BibTeX
@article{Zhang2026,
author = {Zhang, Heng and Yang, Wanxiang and Ge, Xiao and Xu, Gang and Gou, Shaohua},
title = {Brigatinib-based targeted drug conjugates afford selective and potent anti-tumor efficacy in the treatment of pancreatic ductal adenocarcinoma},
journal = {Bioorganic Chemistry},
year = {2026},
volume = {180},
pages = {110247},
doi = {10.1016/j.bioorg.2026.110247}
}
EUVIMED